Biotricity to Host Third Quarter Fiscal Year 2024 Financial Results and Business Update Call on February 21st
February 19, 2024
Petros Pharmaceuticals to Pursue 505(B)(2) Pathway for H-100, Company’s Novel Topical Investigational Treatment for Peyronie’s Disease Which Impacts More Than 1 in 10 Men in the US
May 3, 2022
Related Post
-
-
Endexx Corporation Announces Strategic Shift in Auditor Services to Bolster Growth and Transparency
February 16, 2024
-
Biotricity Advances Towards Breakeven Milestone – Set to Announce Record Margins and Operational Efficiency for Third Quarter of Fiscal Year 2024
February 14, 2024
-
Petros Pharmaceuticals Enters into AI Licensing Agreement with Leading Multi-Billion-Dollar Software Provider
February 14, 2024